Epilepsy is one of the most common neurological disorders in the world. According to the World Health Organization, around 50 ...

Novartis recently announced plans to massively expand its North Carolina presence, creating hundreds of jobs. Now North ...

Indoco Remedies receives USFDA approval to market generic Lacosamide oral solution for epilepsy treatment. Manufactured in Goa facility.

Extratemporal epileptogenic zones, male sex, and obesity are strongly associated with SUDEP risk among patients with drug-resistant epilepsy.

New study suggests that an experimental peptide developed at the Hebrew University may reduce recurring seizures and support ...

SEQSTER, the leading healthcare technology company and the data connection, collection, and orchestration layer for patient ...

A new study published in the journal Medicine by researchers from Korea University College of Medicine provides further ...

A new treatment developed by Israeli researchers could change how epilepsy is managed by not only reducing seizures but also helping protect the brain from long-term damage, according to the Hebrew ...

Indoco Remedies has secured final USFDA approval for its generic Lacosamide oral solution, a bioequivalent of Vimpat, enabling the company to market this essential epilepsy treatment in the US from ...

The SCN2A Foundation today announced a research collaboration with Unravel Biosciences, Inc., an AI-enabled therapeutics ...

Qelbree-led growth, Sage acquisition synergies, and <4x forward P/S support ~25% upside into 2026. Click for more on SUPN ...

Orphan Drug Designation applies to approximately 50,000 Patients who predominantly suffer from severe chronic pain due ...